JNJ - Emergent Bio receives modified task order for expansion of JNJ's COVID-19 vaccine

Emergent BioSolutions (EBS) has received a contract modification from BARDA to increase the original task order by $23M.The additional sum will be used to purchase biologics manufacturing equipment specific to Johnson & Johnson’s (JNJ) COVID-19 vaccine for the potential expansion of bulk drug substance.In addition, Emergent expects to align with the U.S. government and AstraZeneca on a mutually agreed ramp down of manufacturing for AZN's COVID-19 vaccine bulk drug substance. Today, Emergent has nine COVID-19 CDMO partnerships.In addition, the company reaffirmed its 2021 financial guidance.In light of recent accidental mixing of JNJ vaccines, the Biden administration has put Johnson & Johnson in charge of the EBS Baltimore plant that ruined millions of vaccines.Also, Emergent's COVID-19 hyperimmune globulin trial missed endpoints.

For further details see:

Emergent Bio receives modified task order for expansion of JNJ's COVID-19 vaccine